Inspire Medical Systems (NYSE:INSP) Price Target Raised to $175.00

20 Dec 2025, 08:20 by Michael Walen · The Markets Daily

Inspire Medical Systems (NYSE:INSP – Free Report) had its target price increased by Royal Bank Of Canada from $125.00 to $175.00 in a research report report published on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has an outperform rating on the stock.

A number of other equities research analysts have also commented on INSP. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Inspire Medical Systems in a research report on Wednesday, December 10th. JPMorgan Chase & Co. increased their target price on Inspire Medical Systems from $82.00 to $118.00 and gave the stock a “neutral” rating in a research note on Tuesday. Wells Fargo & Company upgraded shares of Inspire Medical Systems from an “equal weight” rating to an “overweight” rating and dropped their target price for the stock from $101.00 to $90.00 in a report on Tuesday, November 4th. Truist Financial upgraded shares of Inspire Medical Systems from a “hold” rating to a “buy” rating and upped their price target for the company from $128.00 to $165.00 in a report on Wednesday, November 26th. Finally, Stifel Nicolaus set a $110.00 price objective on shares of Inspire Medical Systems and gave the stock a “buy” rating in a research report on Monday, November 24th. Eleven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems currently has an average rating of “Moderate Buy” and a consensus price target of $138.88.

Read Our Latest Research Report on INSP

Inspire Medical Systems Stock Up 1.2%

Shares of NYSE INSP opened at $96.39 on Wednesday. Inspire Medical Systems has a twelve month low of $70.77 and a twelve month high of $216.01. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 65.57, a P/E/G ratio of 10.98 and a beta of 0.70. The company’s fifty day moving average is $99.58 and its 200-day moving average is $103.72.

Inspire Medical Systems (NYSE:INSP – Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.53. The business had revenue of $224.50 million during the quarter, compared to analysts’ expectations of $220.39 million. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 EPS. On average, research analysts anticipate that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Shawn Mccormick sold 2,000 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the transaction, the director owned 26,046 shares in the company, valued at approximately $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

Several institutional investors and hedge funds have recently added to or reduced their stakes in INSP. FNY Investment Advisers LLC bought a new position in shares of Inspire Medical Systems in the 3rd quarter valued at about $211,000. Caitong International Asset Management Co. Ltd boosted its position in Inspire Medical Systems by 5,300.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,080 shares of the company’s stock valued at $80,000 after purchasing an additional 1,060 shares during the last quarter. XTX Topco Ltd boosted its position in Inspire Medical Systems by 4.3% during the third quarter. XTX Topco Ltd now owns 7,289 shares of the company’s stock valued at $541,000 after purchasing an additional 300 shares during the last quarter. Voleon Capital Management LP bought a new position in Inspire Medical Systems in the third quarter valued at approximately $5,826,000. Finally, Verition Fund Management LLC grew its stake in Inspire Medical Systems by 336.3% in the third quarter. Verition Fund Management LLC now owns 71,695 shares of the company’s stock valued at $5,320,000 after purchasing an additional 55,261 shares in the last quarter. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems News Summary

Here are the key news stories impacting Inspire Medical Systems this week:

Positive Sentiment: Several brokerages have signaled confidence by raising targets or keeping bullish ratings — Mizuho lifted its target to $130 and maintained Outperform, and JPMorgan raised its target to $118; Bank of America and Robert W. Baird issued buy/reaffirmations, supporting upside expectations. Mizuho Raises INSP Price Target JPMorgan Boosts INSP PT Baird Reaffirms Buy
Neutral Sentiment: Market commentary is revisiting valuation after a sharp share slide — useful for investors assessing risk/reward but dependent on how reimbursement and legal issues evolve. Revisiting Valuation
Negative Sentiment: Numerous law firms have filed investor alerts and securities class-action notices tied to a large share drop (cited ~$42.04) alleging concealed Medicare billing software failures and inventory problems — multiple firms are soliciting lead-plaintiff roles ahead of a Jan. 5, 2026 deadline. This raises litigation risk, potential costs and distraction for management. Rosen Law Firm Notice PR Newswire Lawsuit Notice
Negative Sentiment: Coverage ties the share decline to a Medicare reimbursement/coding change and alleged operational issues; articles explain a sharp drop (reported 23–30% moves) and cite the Medicare policy shift as the proximate catalyst — a fundamental reimbursement risk that could materially affect revenue if not resolved or mitigated. Why INSP Is Down After Medicare Coding Shift AAII Explainer

Inspire Medical Systems Company Profile

(Get Free Report)

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.